ClinicalTrials.gg
CompletedNCT03992430MIS51ONUpdated Nov 10, 2026

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

A Phase 3 interventional study of Eteplirsen in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Completed at 59 sites in 26 countries. Open to male participants aged 4 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
4 Years to 13 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
Largest of 11
160 · median 15
Started
2020
with 1 other
Phase 3
2 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one has the largest enrollment, is one of 2 that started in 2020, is one of 2 in phase 3, and was the 10th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 13 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram [mg/kg] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51.

03

Conditions studied

  • Muscular Dystrophy, Duchenne

Keywords

  • Duchenne muscular dystrophy
  • Exon Skipping
  • Exon 51
  • North Star Ambulatory Assessment
  • Ambulatory
  • DMD
  • Pediatric
  • Duchenne
  • EXONDYS
  • MIS51ON
04

Who can participate

Ages eligible
4 Years to 13 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a male with an established clinical diagnosis of DMD and an out-of-frame deletion mutation of the DMD gene amenable to exon 51 skipping.
  • Ambulatory participant, able to perform TTRISE in 10 seconds or less at the time of screening visit.
  • Able to walk independently without assistive devices.
  • Have intact right and left biceps muscles or an alternative upper arm muscle group.
  • Have been on a stable dose or dose equivalent of oral for at least 12 weeks prior to randomization and the dose is expected to remain constant (except for modifications to accommodate changes in weight and stress-related needs as per the recently published guidelines throughout the study.
  • For ages 7 years and older, has stable pulmonary function (forced vital capacity ≥50 percent (%) of predicted and no requirement for nocturnal ventilation). For ages 4 to 6 years, does not require support from ventilator or non-invasive ventilation at time of screening.

Exclusion criteria

Exclusion Criteria:

  • Use of any pharmacologic treatment (other than ) within 12 weeks prior to randomization.
  • Current or previous treatment with any other experimental pharmacologic treatment for DMD or any prior exposure to antisense oligonucleotide, gene therapy or gene editing; except the following: Ezutromid in the last 12 weeks prior to first dose; Drisapersen in the last 36 weeks prior to first dose; Suvodirsen in the last 12 weeks prior to first dose; Vamorolone in the last 12 weeks prior to first dose; Eteplirsen (previous or current use); and Tamoxifen in the last 4 weeks prior to first dose.
  • Major surgery within 3 months prior to randomization.
  • Presence of any other significant neuromuscular or genetic disease other than DMD.
  • Presence of any known impairment of renal function and/or other illness.
  • Has evidence of cardiomyopathy, as defined by less than \<50% on the screening echocardiogram or Fridericia's correction formula () ≥450 millisecond based on the screening (ECGs).

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Part 1: Eteplirsen

    Participants will receive eteplirsen 100 mg/kg once weekly for at least 4 weeks, followed by eteplirsen 200 mg/kg once weekly for at least 4 weeks.

    Drug: Eteplirsen

  • Active comparator
    Part 2: Eteplirsen 30 mg/kg

    Randomized participants will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.

    Drug: Eteplirsen

  • Experimental
    Part 2: Eteplirsen 100 mg/kg

    Randomized participants will receive eteplirsen 100 mg/kg once weekly for up to 144 weeks.

    Drug: Eteplirsen

  • Experimental
    Part 2: Eteplirsen 200 mg/kg

    Randomized participants will receive eteplirsen 200 mg/kg once weekly for up to 144 weeks.

    Drug: Eteplirsen

Interventions

  • Solution for intravenous (IV) infusion.

    Also known as: AVI-4658, EXONDYS 51, EXONDYS

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of Adverse Events (AEs)

    Time frame: Up to Week 148

  2. Part 2: Change From Baseline at Week 144 in the NSAA Total Score (for Final Analysis)

    Time frame: Baseline, Week 144

  3. Part 2: Change from Baseline at Week 72 or Week 96 in NSAA Total Score (for Conditional Efficacy Interim Analysis)

    Time frame: Baseline, Week 72 or Week 96

Secondary outcomes

  1. Part 2: Change From Baseline in Time to Rise From the Floor, Time to Complete 10-Meter Walk/Run, and the Timed Stair Ascend Test

    Time frame: Baseline, Week 144

  2. Part 2: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT)

    Time frame: Baseline, Week 144

  3. Part 2: Change from Baseline at Week 144 in Forced Vital Capacity Percent Predicted (FVC%p)

    Time frame: Baseline, Week 144

  4. Part 2: Time to Loss of Ambulation (LOA)

    Time frame: Baseline up to Week 144

  5. Part 2: Change From Baseline in Skeletal Muscle Dystrophin Expression

    Time frame: Baseline, Postdose (at Week 24, Week 48, or Week 144)

  6. Part 2: Incidence of Adverse Events (AEs)

    Time frame: Baseline up to Week 148

  7. Part 2: Pharmacokinetic (PK) Plasma Concentration of Eteplirsen

    Time frame: 0 (predose) to 2 hours postdose up to Week 144

07

Study locations

59 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Sep 2026, 73 months.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 73 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2019
First posted
Jun 20, 2019
StartActual
Jul 13, 2020
Primary completionActual
Sep 7, 2026was Oct 2026
CompletionActual
Sep 7, 2026was Oct 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Primary completion
Oct 31, 2026→Sep 7, 2026 (actual)
Nov 10, 2026
Study completion
Oct 31, 2026→Sep 7, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Primary completion Oct 31, 2026→Sep 7, 2026 (now actual)
    Study completion Oct 31, 2026→Sep 7, 2026 (now actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03992430
Responsible party
Sponsor
First posted
Jun 20, 2019
Start date
Jul 13, 2020
Primary completion
Sep 7, 2026
Completion
Sep 7, 2026
Last update
Nov 10, 2026

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion